Science News
from research organizations

Newly discovered tumor-suppressor gene affects melanoma survival

Date:
October 26, 2015
Source:
Weizmann Institute of Science
Summary:
Scientists have found a tumor suppressor gene, RASA2, that drives a particularly deadly form of melanoma as well as regulates a key protein, RAS, that is a major oncogene. The discovery is "highly likely to have direct clinical relevance," say researchers.
Share:
FULL STORY

Of the hundreds of genes that can be mutated in a single case of melanoma, only a handful may be true "drivers" of cancer. In research that recently appeared in Nature Genetics, a Weizmann Institute of Science team has now revealed one of the drivers of a particularly deadly subset of melanomas that is seeing a rise in new cases. This gene is a newly identified member of a group of genes called tumor suppressor genes, and is mutated in some 5.4% of melanomas. Furthermore, its expression was found to be lost in over 30% of human melanomas; this loss, according to the research, was associated with reduced patient survival. The discovery might open new doors to understanding how this cancer grows and spreads, and may lead in the future to new directions in treatment.

Prof. Yardena Samuels and her team in the Weizmann Institute of Science's Department of Molecular Cell Biology were specifically searching for tumor suppressor genes in their database, which consists of more than 500 melanoma genomes and exomes -- protein-building sequences -- making it the largest melanoma dataset to date. As their name suggests, tumor suppressor genes normally inhibit cell growth, including that of cancer cells. However, when mutated, they act like defective brakes on cellular proliferation. Thus, studying these genes is crucial in cancer biology. "The identification of targetable alterations in melanoma is an urgent need. An in-depth understanding of the functional effects of mutations in these genes is the first step toward revealing the underlying mechanism of melanoma growth," says Dr. Nouar Qutob, a postdoctoral fellow in Prof. Samuels' lab who participated in this research.

Indeed, the melanoma genome sequences contained mutations in known tumor suppressor genes, but there was also a new gene -- RASA2 -- that stood out during the team's search. Their next step was to conduct a series of functional experiments to understand exactly what this gene does. They cloned both the normal protein and the most recurrent mutated versions to see their effects on melanoma cells, finding that RASA2 regulates a key protein in the cell, called RAS. RAS has been identified as a major oncogene that contributes to the unchecked growth of cells. When the team restored the production of the RAS protein in melanoma cells that harbored RASA2 mutations, the cells stopped growing and eventually died.

Patients with dysfunctional RAS pathways tend to have a worse prognosis than those with other types of melanomas, and until now, scientists have not managed to create drugs that can target this pathway. "As the RAS pathway is highly dysregulated in cancer, the discovery of an alternative mechanism for its activation is likely to stimulate an avalanche of further research in this field, and is highly likely to have direct clinical relevance. We are now going to focus on RASA2, to find out what proteins it communicates with in healthy cells and melanoma, as well as in the cells' response to targeted therapy," says Prof. Samuels.

"Most targeted cancer therapies nowadays work by inhibiting the products of oncogenes that are overactive in melanoma cells. However, loss or mutations in tumor suppressor genes like RASA2 also contribute to melanoma development; therefore, discovering and studying RASA2 targets and partners will be our next aim," says Rand Arafeh, a PhD student in Prof. Samuels' lab and lead author of the paper.


Story Source:

Materials provided by Weizmann Institute of Science. Note: Content may be edited for style and length.


Journal Reference:

  1. Rand Arafeh, Nouar Qutob, Rafi Emmanuel, Alona Keren-Paz, Jason Madore, Abdel Elkahloun, James S Wilmott, Jared J Gartner, Antonella Di Pizio, Sabina Winograd-Katz, Sivasish Sindiri, Ron Rotkopf, Ken Dutton-Regester, Peter Johansson, Antonia L Pritchard, Nicola Waddell, Victoria K Hill, Jimmy C Lin, Yael Hevroni, Steven A Rosenberg, Javed Khan, Shifra Ben-Dor, Masha Y Niv, Igor Ulitsky, Graham J Mann, Richard A Scolyer, Nicholas K Hayward, Yardena Samuels. Recurrent inactivating RASA2 mutations in melanoma. Nature Genetics, 2015; DOI: 10.1038/ng.3427

Cite This Page:

Weizmann Institute of Science. "Newly discovered tumor-suppressor gene affects melanoma survival." ScienceDaily. ScienceDaily, 26 October 2015. <www.sciencedaily.com/releases/2015/10/151026180922.htm>.
Weizmann Institute of Science. (2015, October 26). Newly discovered tumor-suppressor gene affects melanoma survival. ScienceDaily. Retrieved May 29, 2017 from www.sciencedaily.com/releases/2015/10/151026180922.htm
Weizmann Institute of Science. "Newly discovered tumor-suppressor gene affects melanoma survival." ScienceDaily. www.sciencedaily.com/releases/2015/10/151026180922.htm (accessed May 29, 2017).

RELATED STORIES